Camzyos Phase 3 Trial Shows Positive Results in Adolescent OHCM, Potential First-in-Class Therapy
BMY sits 38% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb announced positive Phase 3 results from its Scout-HCM trial for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (OHCM). The trial successfully met its primary endpoint, demonstrating significant left ventricular outflow tract (LVOT) gradient reduction and a safety profile consistent with that observed in adults. This is a material development as it positions Camzyos as a potential first targeted pharmacological therapy for OHCM in adolescents, significantly expanding its addressable market beyond the currently approved adult indication. This positive news, following recent favorable data for another drug, Cobenfy, highlights the company's ongoing pipeline advancements. Traders will be watching for subsequent regulatory submissions and potential label expansion.
At the time of this announcement, BMY was trading at $58.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $119.2B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.